Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylephedrine SCHEMBL99674 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL907777 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL7496690 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL2712293 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL11959977 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL907677 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL338478 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL99673 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL8083321 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1AOC3GAAADRA2C | |
| Methylephedrine SCHEMBL68363 | 0.98 | ALDH1A1 (0.96) | KDM4EALDH1A1AOC3GAAADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322482-B1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | TAP PHARMACEUTICALS AG (CH) | 2023-07-26 | — | — | EP | claimed |
| WO-2026102437-A1 | METHODS OF TREATING FRAGILE X SYNDROME USING PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4698542-A1 | 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS | Incyte Corporation (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4688752-A1 | IRHOM2 INHIBITORS AND USES THEREOF | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4680238-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF ASTHMA | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025245087-A1 | HETEROCYCLIC COMPOUNDS AS PARG INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250228644-A1 | METHODS FOR MARKING A TARGET LOCATION FOR A MEDICAL PROCEDURE | EPHEMERAL SOLUTIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-11241411-B2 | Benzonatate modified release solid tablets and capsules | TRIS PHARMA, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022026645-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | MELIOR PHARMACEUTICALS I, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2017203459-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-11-30 | — | — | WO | disclosed |
| US-20120083603-A1 | HIGH STABILITY POLYIONIC LIQUID SALTS | SIGMA-ALDRICH CO. LLC (US) | 2012-04-05 | — | — | US | disclosed |
| US-8097721-B2 | polycationic or polyanionic molecules; use as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS); thermal stability; tris(anion) such as tris(sulfonate) or tris(cation) groups such as imidazolium, pyrrolidinium, ammonium | SIGMA-ALDRICH CO. LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-7772405-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2008-10-23 | — | — | US | disclosed |
| EP-1966127-A1 | CARBONYL ASYMMETRIC ALKYLATION | Sandoz AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20080210858-A1 | High Stability Polyionic Liquid Salts | SIGMA-ALDRICH CO. NEWCO INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2007082771-A1 | CARBONYL ASYMMETRIC ALKYLATION | SANDOZ AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241411-B2 | Benzonatate modified release solid tablets and capsules | SBDS, SI, BPGM | KDM4E 1893/4885ALDH1A1 2102/4885AOC3 1929/4885 |
| US-20080210858-A1 | High Stability Polyionic Liquid Salts | PUF60, POLI, PARG | KDM4E 4398/4885ALDH1A1 4720/4885AOC3 4342/4885 |
| US-20120083603-A1 | HIGH STABILITY POLYIONIC LIQUID SALTS | PUF60, POLI, PARG | KDM4E 4398/4885ALDH1A1 4720/4885AOC3 4342/4885 |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | REN, AGTR2, AGTR1 | KDM4E 789/4885ALDH1A1 1161/4885AOC3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.